CClinicalTrials.gg
CompletedNCT03264248Updated May 21, 2019Results posted

Daily Weight Feedback for Wheelchair Users to Promote Weight Loss

An interventional study of E-Scale in Overweight and Obesity and Depression, sponsored by Jonathan Pearlman. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Jonathan Pearlman · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goals of the proposed study are to test the usability, feasibility and preliminary efficacy of the E-Scale with wheelchair users. The E-scale was developed as a weight monitoring technology for wheelchair users. Up to fifteen overweight or obese wheelchair users will be enrolled in a 13 week study that includes standard behavioral treatment (SBT) for weight loss, which focuses on diet, physical activity, and behavioral strategies (e.g., goal setting, self-monitoring) to support lifestyle changes specifically for people with mobility impairments. The subjects will also be provided the E-scale to track their weight daily. The outcome measure include usefulness (subjective feedback from a survey about the program/E-scale), feasibility (accuracy and repeatable measurements from the E-scale) and efficacy (improvements in weight and other measures of health) of the weight loss program coupled with the E-scale at the end of 13 weeks. The primary hypothesis is that the E-scale coupled with the weight loss intervention will result in significant improvements in weight, abdominal girth, body fat percentage, and the Center for Epidemiologic Studies Depression Scale (CES-D).The results may inform the refinement of this technology to increase its applicability for wheelchair users to independently monitor their weight in their own homes while attempting to lose weight.

Read the detailed description

Wheelchair users have about twice the prevalence of obesity than the general population. There is also very little or no technology to which they have access to measure their weight frequently in their homes. Research however, has shown that monitoring your body weight frequently (i.e. daily) yields significantly better weight loss and weight maintenance results. This research has never included wheelchair users because they have not had access to technology to be able to measure their weight daily. The E-scale was developed as a weight monitoring technology for wheelchair users and has been tested for precision and accuracy in the laboratory. The goal of this study is to determine the usefulness, feasibility and efficacy of the E-scale system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users.

Up to fifteen overweight or obese wheelchair users will be enrolled in a 13 week study that includes standard behavioral treatment (SBT) for weight loss, which focuses on diet, physical activity, and behavioral strategies (e.g., goal setting, self-monitoring) to support lifestyle changes specifically for people with mobility impairments. The subjects will also be provided the E-scale to track their weight daily. The outcome measure include usefulness (subjective feedback from a survey about the program/E-scale), feasibility (accuracy and repeatable measurements from the E-scale) and efficacy (improvements in weight and other measures of health) of the weight loss program coupled with the E-scale at the end of 13 weeks.

Study hypotheses are:

Hypothesis 1: The E-scale will be useful based on self-reported feedback from wheelchair users by more than 50% stating that the E-scale is easy to use, their preferred weight monitoring system, them feeling that they would use the E-scale if it was available for them to purchase.

Hypothesis 2: The E-scale will be feasible by providing accurate (+/- 2 lbs. from a calibrated scale measurement) and repeatable (\<3lbs difference from day-to-day) weight measurements and by the wheelchair users continuing to use the scale more than 70% of the days of the study.

Hypothesis 3: The E-scale coupled with the weight loss intervention will demonstrate efficacy by wheelchair users having significant improvements in weight, abdominal girth, body fat percentage, and the Center for Epidemiologic Studies Depression Scale (CES-D).

This research will determine whether wheelchair users find the E-scale to be useful and feasible as a way to monitor their weight in their homes. It will also show whether wheelchair users, like the general population, have better weight loss outcomes when they monitor their weight daily. This could lead to refinement of the E-scale and a push for more available technology for wheelchair users to monitor their weight at home which could in turn lead to a decrease in the prevalence of obesity among wheelchair users.

02

Conditions studied

  • Overweight and Obesity
  • Depression

Keywords

  • obesity
  • overweight
  • wheelchair
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Use Wheelchair as primary means of mobility
  • Uses a bed with 4 legs
  • Body mass index (BMI) ≥27 and ≤40.0
  • Has daily access to Internet
  • Currently owns or willing to use an android device
  • Provides physician clearance to participate in a weight loss intervention
  • Speaks English

Exclusion criteria

Exclusion Criteria:

  • Presence of an unstable condition requiring physician-supervised diet and exercise (e.g., diabetes, recent myocardial infarction)
  • Presence of condition precluding engagement in exercise at moderate intensity (e.g., asthma, congestive heart failure, etc.)
  • Pregnancy or intention to become pregnant during study
  • Currently being treated for any psychological issues or problems, taking any psychotropic medications, or receiving treatment with psychotropic medications within the previous 6 months
  • Reported alcohol intake > 4 drinks/day
  • Reported participation in a formal weight loss program, loss of ≥5% weight in the past 6 months, or current use of weight loss medication.
  • History of bariatric surgery (lap-band, gastric bypass, etc.)
  • Planned extended vacations, absences, or relocation during study
  • A score ≥20 on the Center for Epidemiologic Studies Depression Scale (CES-D)
  • A classification of Anorexia Nervosa, Bulimia Nervosa or Binge Eating Disorder on the Eating Disorder Diagnosis Scale (EDDS)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    E-Scale

    E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users

    Device: E-Scale

Interventions

  • DeviceE-Scale

    Daily bodyweight system used under legs of bed

05

What researchers measure

Primary outcomes

  1. Weight Change

    Change in body weight

    Time frame: baseline and 13 weeks

Secondary outcomes

  1. Abdominal Girth Change

    Change in abdominal girth

    Time frame: baseline and 13 weeks

  2. Body-fat Percentage Change

    Change in body fat percentage

    Time frame: 13 weeks

  3. Depression Score at Baseline

    Depression scale determined by using the Center for Epidemiology Studies-Depression score. In scoring the CES-D, a value of 0, 1, 2 or 3 is assigned to a response depending upon whether the item is worded positively or negatively.. Possible range of scores is averaged to equal 0 to 60, with the higher scores indicating the presence of more symptomatology

    Time frame: Baseline only

06

Results

Posted May 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneE-Scale
Started9
Completed9
Not completed0

Outcome measures

PrimaryWeight Change

Change in body weight

Time frame:
baseline and 13 weeks
Reported as:
Mean · pounds
Weight Change
poundsE-Scale
Baseline196.0 ± 38.0
Final192.8 ± 36.4
SecondaryAbdominal Girth Change

Change in abdominal girth

Time frame:
baseline and 13 weeks
Reported as:
Mean · inches
Abdominal Girth Change
inchesE-Scale
Baseline45.1 ± 4.8
Final44.4 ± 4.8
SecondaryBody-fat Percentage Change

Change in body fat percentage

Time frame:
13 weeks
Reported as:
Mean · percentage of pounds
Body-fat Percentage Change
percentage of poundsE-Scale
Baseline33.3 ± 10.5
Final32.9 ± 9.8
SecondaryDepression Score at Baseline

Depression scale determined by using the Center for Epidemiology Studies-Depression score. In scoring the CES-D, a value of 0, 1, 2 or 3 is assigned to a response depending upon whether the item is worded positively or negatively.. Possible range of scores is averaged to equal 0 to 60, with the higher scores indicating the presence of more symptomatology

Time frame:
Baseline only
Reported as:
Mean · units on a scale
Depression Score at Baseline
units on a scaleE-Scale
Depression Score at Baseline4.8 ± 3.6

Adverse events

Collected over Not collected for this study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E-Scale———

Baseline characteristics

Age, Continuous
Age, Continuous(years)E-Scale
Mean48.8 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)E-Scale
Female4
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)E-Scale
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)E-Scale
United States9
Initial Weight
Initial Weight(lbs.)E-Scale
Mean196.0 ± 38.0
Initial BMI
Initial BMI(kg/m^2)E-Scale
Mean33.6 ± 3.7
Initial Abdominal Girth
Initial Abdominal Girth(inches)E-Scale
Mean45.1 ± 5.6
Initial Body Fat Percentage
Initial Body Fat Percentage(percentage fat)E-Scale
Mean33.3 ± 10.5

2 further baseline measures are reported on the registry.

07

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15206, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 5, 2018
  • Informed consent form · Jun 5, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Portions of the data may be made available upon request

09

Registry details

Key details

Study ID
NCT03264248
Lead sponsor
Jonathan Pearlman
Collaborators
Paralyzed Veterans of America
Responsible party
Jonathan Pearlman (Associate Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Aug 29, 2017
Start date
Jul 1, 2017
Primary completion
Feb 5, 2018
Completion
Feb 9, 2018
Results posted
May 21, 2019
Last update
May 21, 2019

Study contacts

Jon Pearlman, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion